ALLMedicine™ Leukemias Center
Research & Reviews 1,862 results
https://clinicaltrials.gov/ct2/show/NCT01087333
May 13th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...
https://clinicaltrials.gov/ct2/show/NCT03805932
May 13th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...
https://clinicaltrials.gov/ct2/show/NCT02390752
May 13th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...
https://clinicaltrials.gov/ct2/show/NCT03366116
May 13th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...
https://doi.org/10.1182/blood.2021012411
Blood Biederstädt A, Rezvani K
May 6th, 2022 - Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for patients with high risk acute leukemias, but unfortunately disease recurrence remains the major cause of death in these patients. Infusion of don...
Guidelines 2 results
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.
Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...
Drugs 249 results see all →
Clinicaltrials.gov 75 results
https://clinicaltrials.gov/ct2/show/NCT01087333
May 13th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biolog...
https://clinicaltrials.gov/ct2/show/NCT03805932
May 13th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but mo...
https://clinicaltrials.gov/ct2/show/NCT02390752
May 13th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...
https://clinicaltrials.gov/ct2/show/NCT03366116
May 13th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two...
https://clinicaltrials.gov/ct2/show/NCT03810196
Mar 22nd, 2022 - The risk of severe graft versus host disease (GVHD) is increased with the use of unrelated and partially matched related donors. T cell depletion reduces the risk of severe GVHD, but immune reconstitution is delayed. Important memory T cells that ...
News 269 results
https://www.onclive.com/view/dr-lin-on-treatment-updates-in-car-t-cell-therapy-in-myeloma
Apr 21st, 2022 - Yi Lin, MD, PhD, hematologist, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses treatment updates in CAR T-cell therapy in multiple myeloma. CD19-targeted CAR T-cell therapy has established a role in variou...
https://www.medscape.com/viewarticle/971835
Apr 8th, 2022 - The preclinical phase of chronic lymphocytic leukemia (CLL) may be exist longer than previously thought, even in adverse-prognostic cases, as suggested by a sequencing analysis of blood samples obtained up to 22 years prior to CLL diagnosis. Previ...
https://www.mdedge.com/hematology-oncology/article/253547/cll/some-leukemias-detectable-16-years-diagnosis
Sharon Worcester
Apr 7th, 2022 - The preclinical phase of chronic lymphocytic leukemia (CLL) may be exist longer than previously thought, even in adverse-prognostic cases, as suggested by a sequencing analysis of blood samples obtained up to 22 years prior to CLL diagnosis. Previ.
https://www.onclive.com/view/dr-stein-on-key-highlights-of-the-augment-101-trial-in-leukemias
Mar 30th, 2022 - Eytan M. Stein, MD, director, Program for Drug Development in Leukemia, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, discusses the key highlights of the phase 1/2 AUGMENT-101 trial (NCT04065399) in leukemias. The ...
https://www.onclive.com/view/tagraxofusp-and-hyper-cvad-represent-treatment-options-for-patients-with-bpdcn
Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...
